P21.
P21 (also written P021) is a small synthetic peptide derivative modeled on a biologically active region of ciliary neurotrophic factor (CNTF).
P21 (also written P021) is a small synthetic peptide derivative modeled on a biologically active region of ciliary neurotrophic factor (CNTF). P21 is research / preclinical, and PepCue grades its published evidence F tier (22/100). Also known as P021 · CNTF-derived peptide mimetic. This is a research reference, not medical or dosing advice.
What it is
P21 (also written P021) is a small synthetic peptide derivative modeled on a biologically active region of ciliary neurotrophic factor (CNTF). It was designed by researchers at the New York State Institute for Basic Research to be an orally active, blood-brain-barrier-penetrant neurotrophic compound. It has been investigated in animal models of Alzheimer's disease, Down syndrome and other neurodegenerative and neurodevelopmental conditions. It is an early-stage research compound that has not been tested in humans.
How it works
P21 is reported to act partly by inhibiting the leukemia inhibitory factor (LIF) signaling pathway and by increasing transcription of brain-derived neurotrophic factor (BDNF). Elevated BDNF is proposed to enhance neurogenesis and synaptic plasticity and to reduce the activity of GSK-3 beta, an enzyme that drives abnormal tau phosphorylation. Through this pathway it is hypothesized to have a disease-modifying effect on tau-related pathology. These mechanisms are drawn from cell-culture and rodent studies.
Mechanism pathways
Raising growth factors that support neuronal survival, synapse formation, and plasticity.
Neurotrophic factors are proteins that keep neurons alive, guide the formation and strengthening of synapses, and support the structural changes underlying learning. The best-studied is brain-derived neurotrophic factor, which acts on the TrkB receptor tyrosine kinase to activate PI3K and Akt signalling for survival and MAPK signalling for growth, and which is required for long-term potentiation, the cellular process most closely associated with memory formation. Nerve growth factor acts similarly through TrkA. A separate system involves hepatocyte growth factor and its receptor tyrosine kinase c-Met, which in neurons is associated with dendritic spine formation and synaptogenesis. Compounds in this group approach the same idea from different angles. Several are short peptides derived from fragments of adrenocorticotropic hormone that lack the hormone's melanocortin-driven corticotropic activity, so they do not raise cortisol. Their best-characterised action in animal and cell studies is upregulation of BDNF and its TrkB receptor in the hippocampus and cortex, along with increased nerve growth factor expression, plus modulation of monoaminergic signalling and inhibition of enkephalin-degrading enzymes. One member of this subgroup is a chemically modified variant designed for greater stability, whose mechanism is inferred from the parent rather than independently established. Others are complex biological mixtures rather than single molecules, prepared from brain tissue, and their activity is attributed to many peptide interactions acting together. Proposed actions include mimicking endogenous neurotrophic factors, supporting neuronal energy metabolism, reducing excitotoxicity, and providing anti-apoptotic and antioxidant effects. Because the active components are not fully defined, batch consistency is an intrinsic issue with this format. A further compound is reported to raise BDNF transcription while inhibiting a cytokine signalling pathway, with downstream reduction of an enzyme implicated in abnormal tau phosphorylation. Another was developed to potentiate hepatocyte growth factor signalling at c-Met. Several honest caveats apply. Most of this evidence comes from rodent and cell-culture work. Some of the brain-derived mixtures are approved and widely used in certain countries while remaining unapproved and unavailable in others, and independent assessments of their clinical benefit have been mixed. For the c-Met compound, the central biochemical evidence for its proposed mechanism came from a publication that was retracted for data fabrication, and c-Met is a well-established oncology target, so chronic potentiation raises an unresolved risk question that no human study has addressed.
The evidence
The evidence for P21 is entirely preclinical and comes largely from a single research group. In triple-transgenic Alzheimer's (3xTg-AD) mice, chronic oral P021 reduced tau hyperphosphorylation and rescued neurogenesis, synaptic markers and cognition (Kazim et al., Neurobiology of Disease 2014). A later study reported that early P021 treatment prevented dendritic and synaptic deficits and cognitive impairment in the same model (Baazaoui and Iqbal, Alzheimer's Research and Therapy 2017). Subsequent work from the same laboratory extended the approach to treatment begun in early postnatal development, again in a transgenic rodent model, and reported prevention of Alzheimer-like behavior and synaptic dysfunction (Journal of Alzheimer's Disease, 2021). A later review by the same investigators frames the compound as a therapeutic opportunity to be tested rather than an established treatment (Biomolecules, 2022). The design of this body of work sets clear limits on what it can support. These are rodent experiments in genetically engineered models that reproduce selected features of human Alzheimer's pathology and that have a long record of poor translation to the clinic. They were conducted by the originating institution rather than by independent replicating laboratories, and the published reports are academic studies, not blinded, multi-site, pre-registered confirmatory trials. The outcomes are surrogate measures: phosphorylated tau, synaptic protein density, neurogenesis markers, and rodent behavioral tasks. None is a clinical endpoint, and treatment durations span weeks to months of animal life rather than years of human disease. What is unknown is more substantial than what has been shown. No human clinical trial of P21 has been completed or registered. There is therefore no Phase 1 dataset, no human pharmacokinetic or bioavailability profile despite the oral-activity claim, no characterized exposure range, and no published formal toxicology package. The contrast with the class it is compared against is stark: approved central nervous system drugs for Alzheimer's disease have moved through sequential Phase 1, 2 and 3 programs enrolling thousands of participants with adjudicated cognitive and functional endpoints, and even candidates that failed later usually established a human tolerability and exposure baseline in Phase 1. P21 has not reached that first step. Positive rodent findings do not establish efficacy or safety in people.
The evidence, in brief
A small synthetic peptide (also written P021) modeled on an active region of ciliary neurotrophic factor, designed to be orally active and brain-penetrant, and reported to raise BDNF and reduce GSK-3 beta-driven tau phosphorylation. Results come from triple-transgenic Alzheimer mouse models: reduced tau hyperphosphorylation, rescued neurogenesis and cognition. The evidence is entirely preclinical and largely from one research group, with no human trials completed or registered.
- Kazim SF et al.: Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in 3xTg-AD miceNeurobiol Dis, 2014 (PMID 25046994)
- Baazaoui N, Iqbal K: Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compoundAlzheimers Res Ther, 2017 (PMID 28655344)
Evidence maturity
An evidence-only reading: approval status, human vs preclinical data, mechanism and safety. Popularity never raises it. Research file #047
Mostly preclinical or mechanistic; little human data.
Findings come mainly from animal models, not people.
Claim receipts
Popular claims about P21, checked against the state of the evidence. The verdict describes evidence maturity, never an invented study result.
Reduced tau hyperphosphorylation and rescued neurogenesis were reported in transgenic mouse models, a class of model with a long record of poor translation to the clinic.
No human clinical trial has been completed or registered, so there is no evidence of cognitive benefit in people, and subjective reports of feeling sharper are strongly placebo-responsive.
Oral activity was reported in rodents; there is no human pharmacokinetic or bioavailability profile to support the same conclusion in people.
The supporting body of work comes largely from the originating laboratory and has not been replicated head to head by an independent group in blinded, pre-registered studies.
The absence of reported adverse events reflects the absence of any monitored human exposure rather than a safety record; there is no Phase 1 dataset and no published toxicology package.
Safety profile
There are no human safety data for P21; all safety information comes from short- to medium-term rodent studies, where it was reported to be tolerated. Long-term effects, appropriate exposure and human toxicology are unknown. No published Phase 1 study has characterized adverse events, dose-limiting toxicity, immunogenicity, or interactions with other medicines in people, and there is no public repeat-dose toxicology, reproductive toxicity, or carcinogenicity dataset of the kind regulators expect before first-in-human testing. Because the proposed mechanism involves raising brain-derived neurotrophic factor and modulating leukemia inhibitory factor signaling, pathways that influence cell growth, survival and inflammation in many tissues, chronic systemic effects cannot be excluded on the basis of rodent behavioral studies alone. Material sold as a research chemical is not quality-controlled for purity or identity. Products of this type are produced outside pharmaceutical good manufacturing practice oversight, are not reliably tested batch by batch for peptide content, related-substance impurities, endotoxin, or residual synthesis reagents, and are labeled for laboratory use rather than administration. A purchaser has no practical way to verify what a vial contains, and the sterility of any reconstituted preparation is unverified. The absence of documented adverse events should not be read as evidence of safety. It reflects the absence of any human exposure under systematic observation, not a record of uneventful use: with no clinical monitoring, no adverse-event reporting channel and no registry, harms would simply go unrecorded. It is not a medicine and is not intended for human use.
Compound notes
- P21 (also written P021) is a small synthetic peptide derivative modeled on a biologically active region of ciliary neurotrophic factor (CNTF).
- It was designed at the New York State Institute for Basic Research to be orally active and able to cross the blood-brain barrier.
- It is reported to inhibit leukemia inhibitory factor signaling and increase transcription of brain-derived neurotrophic factor, which is in turn proposed to enhance neurogenesis and reduce GSK-3 beta-driven tau phosphorylation.
- The evidence is entirely preclinical and largely from one research group, in triple-transgenic Alzheimer's and Down syndrome mouse models.
Cerebrolysin has been through many randomized human trials, contested as the results are. P21 has never been tested in people, so every claim about it rests on rodent work.
- There are no human safety data; all information comes from short- to medium-term rodent studies.
- Not approved by the FDA or any other authority, and it has no approved medical use.
- Material sold as a research chemical is not quality-controlled for purity or identity.
Regulatory status
P21 is not approved by the FDA or any other regulatory authority and has no approved medical use. It exists only as a preclinical research compound. This content is educational only and contains no dosing guidance.
Sold research-use-only; human evidence is limited or preclinical.
By the numbers
- 01Synthetic peptide modeled on an active region of ciliary neurotrophic factor (CNTF).
- 02Designed to be orally active and to cross the blood-brain barrier.
- 03Proposed to raise BDNF and lower GSK-3 beta-driven tau phosphorylation.
- 04Studied in 3xTg-AD Alzheimer and Down syndrome mouse models.
- 05Evidence is preclinical only and largely from one research group.
- 06No human trials; not approved anywhere.
P21: research formats
Choose the format you are researching to see route-specific notes.
Designed to be orally active in animals, but never tested in humans, so no human format exists.
P21 is a small synthetic peptide modeled on an active region of ciliary neurotrophic factor and engineered to be orally active and blood-brain-barrier-penetrant. That design intent is real, but it was pursued in mouse models of Alzheimer's disease and Down syndrome. There are no human trials, so nothing establishes a human route, schedule, or tolerated exposure, and this page presents no example amounts.
Oral activity demonstrated in a mouse model is a property of the molecule in that model, not a human administration format. Bioavailability, metabolism, and tolerability in people are all unmeasured.
The evidence is preclinical and largely from one research group. P21 has no approval anywhere and no approved medical use.
Sources
Every factual claim above resolves to a real, published source.
- Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's diseaseKazim SF et al. Neurobiol Dis, 2014 (PMID 25046994)
- Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compoundBaazaoui N, Iqbal K. Alzheimers Res Ther, 2017 (PMID 28655344)
- Neurotrophic Treatment Initiated During Early Postnatal Development Prevents the Alzheimer-Like Behavior and Synaptic DysfunctionBaazaoui N, Iqbal K. J Alzheimers Dis, 2021 (PMID 34057082)
- Alzheimer's Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic CompoundBaazaoui N, Iqbal K. Biomolecules, 2022 (PMID 36291618)
- ClinicalTrials.gov: P021 / neurotrophic peptide registrationsRegistry search, used to confirm the absence of human trials
Cite this page
PepCue. “P21: the evidence.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/p/p21.
Log your doses, run the vial math, and keep a provider-ready record in PepCue.